Theoretical Study On The Reaction Mechanism Of Gecl3ch2ch2cooh+h2o→gecl2ohch2ch2cooh+hcl

The mechanism and dynamical properties for the title reaction have been investigated theoretically. Three reaction pathways have been found. Geometries, vibrational frequencies, infra-red (IR) intensities and relative energies for various stationary points in the three reaction channels have been determined respectively. The corresponding rate constants at the B3LYP/6-31++G(2d,2p) level have been deduced over a wide temperature range of 200–2000 K by using canonical variational transition state theory with small curvature tunnelling effect. Solvent effects are taken into account via the Onsager model of self-constant reaction field at the same level of theory. This preliminary study shows that the complex formation is favoured by the use of water solvent.     

Zum Ged?ch tnis von Oberpfarrer Dr. Lindner, Quedlinburg

Ohne Zusammenfassung     

谷子显性雄性不育基因“Ms~（ch）”的细胞质转换

通过种间杂交和连续置换回交,选育出具有轮生狗尾草（Ｓ,ｖｅｒｔｉｃｉｌｌａｔａ（Ｌ．）Ｂｅａｕｖ．）细胞质的谷子（Ｓｅｔａｒｉａｉｔａｌｉｃａ（Ｌ．）Ｂｅａｕｖ．）核质杂种,以带有上位基因Ｒｆ的显性核不育植株为父本与此核质杂种杂交,已将显性核不育基因导入轮生狗尾草细胞质中,从其分离后代中选出了具有显性核不育基因的新核质杂种,为谷子的三系选育和细胞质研究创造了新工具,也为核互作杂优利用增加了核质互作优势新机制。     

Pharmacokinetics and stability of the ch14.18–interleukin-2 fusion protein in mice

The fusion protein formed from ch14.18 and interleukin-2 (ch14.18-IL-2), shown to exhibit antitumor efficacy in mouse models, consists of IL-2 genetically linked to each heavy chain of the ch14.18 chimeric anti-GD2 monoclonal antibody. The purpose of this study was to determine the pharmacokinetics of ch14.18-IL-2 in mice and assess its stability in murine serum. Following i.v. injection, the fusion protein was found to have a terminal half-life of 4.1 h. Detection of IL-2 following injection of the ch14.18-IL-2 fusion protein showed a similar half-life, indicating that the fusion protein prolongs the circulatory half-life of IL-2. Detection of human IgG1 following injection of ch14.18-IL-2 showed a terminal half-life of 26.9 h. These data suggested that the native fusion protein is being altered in vivo, resulting in a somewhat rapid loss of detectable IL-2, despite prolonged circulation of its immunoglobulin components. In vitro incubation of the ch14.18-IL-2 fusion protein in pooled mouse serum at 37 degrees C for 48 h resulted in a loss of its IL-2 component, as detected in enzyme-linked immunosorbent assay systems and in proliferation assays. Polyacrylamide gel electrophoresis and Western blot analysis of the fusion protein incubated in mouse serum at 37 degrees C indicated that the ch14.18-IL-2 is cleaved, resulting in a loss of the 67-kDa band (representing the IL-2 linked to the IgG1 heavy chain) and the detection of a band of more than 50 kDa, slightly heavier than the IgG1 heavy chain itself. This suggests that the fusion protein is being cleaved in vitro within the IL-2 portion of the molecule. These studies show that (1) ch14.18-IL-2 prolongs the circulatory half-life of IL-2 (compared to that of soluble IL-2) and (2) the in vivo clearance of the fusion protein occurs more rapidly than the clearance of the ch14.18 antibody itself, possibly reflecting in vivo cleavage within the IL-2 portion of the molecule, resulting in loss of IL-2 activity.